An observational study in Stroke, Ischemic, Strokes Thrombotic and Stroke, sponsored by University of Monastir. Recruiting at 1 site in Tunisia. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-02-28.
Sponsored by University of Monastir · Observational
Study the prevalence of strokes in the emergency department (ED) and their possible eligibility for thrombolysis.
The diagnosis and management of strokes represent a great emergency that requires multidisciplinary teams and an organization of the care chain from the collection of patients at the site of the stroke to follow-up care.
That is why it is necessary to identify the prevalence of stroke in the ED in Tunisia and to evaluate their eligibility for thrombolysis.
21 studies on the registry are indexed under Thrombotic Stroke; 8 are open to participants now.
Browse Thrombotic Stroke studies →University of Monastir is the lead sponsor of 114 studies on the registry; 29 are open to participants now.
Compared within Thrombotic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ischemic Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →
All patients with stroke symptoms and accept to enroll the study .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Stroke prevalence
After entering the ED , the patient will have a radiological and biological screening to establish his right diagnostic and then we have stroke prevalence in the ED.
Time frame: 1day
Modified Rankin Scale (MRS) score change
After discharge from ED, patients were called back in order to know information about the quality of life and the search for persistent complications.
Time frame: After a month , six month , 1 year
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.